Half a century of advancements in biomedical science paved the way for today’s powerful weight-loss drugs like Ozempic — so ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Following the recent recommendation of its advisory committee, the U.S. FDA gave the nod to Zevra Therapeutics Inc.’s ...

Novo Nordisk and Eli Lilly are offering discounts to encourage more insurance coverage of the medicines, which carry price ...

Novo Nordisk's U.S.-listed shares lost ground Friday after a study of the pharmaceutical firm’s latest obesity treatment ...

Discounts of as much as half on the $1,000-plus-a-month injectables are meant to induce insurers to offer coverage to workers ...

By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk's shares fell nearly 5% on Friday after ...

Eli Lilly and Novo Nordisk the pharmaceutical heavyweights selling popular weight-loss injections are each dangling discounts to gain an edge and to ...

Ozempic maker Novo Nordisk (NVO) announced mixed results today for a phase 2 trial of an experimental weight loss pill that ...

Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for ...